The drug firm believes it is the first company to have filed a substantially-complete ANDA containing a Paragraph IV Certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of potential launch of the product under certain circumstances.
)
As per industry estimates, Tabrecta recorded sales of USD 126 million in the US market for the year 2023. Image: Pixabay/Representational
